Geoffrey L Uy

Trials

Studies that name Geoffrey L Uy as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:06 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT07617363 · ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

  Washington University School of Medicine · not yet recruiting · Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome · principal investigator
• Ph2/Ph3
  NCT03701308 · Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

  National Cancer Institute (NCI) · active not recruiting · Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT02763384 · BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

  Washington University School of Medicine · terminated · T-Acute Lymphoblastic Leukemia, Adult T Lymphoblastic Lymphoma · principal investigator
• Ph2
  NCT01253070 · Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

  National Cancer Institute (NCI) · completed · Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 · principal investigator
• Ph1/Ph2
  NCT00906945 · Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

  Washington University School of Medicine · completed · Leukemia, Myeloid, Acute · principal investigator
• Ph1/Ph2
  NCT00512252 · AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

  Washington University School of Medicine · completed · Leukemia, Myeloid, Acute · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• 04 Hematopoietic Development and Malignancy Program
  P30CA091842 · NCI · WASHINGTON UNIVERSITY · fiscal years 2026 · $91,807 awarded in 2026
  Same name and institution; not confirmed by an ID
• Clinician Scientist in Leukemia
  R50CA275927 · NCI · WASHINGTON UNIVERSITY · fiscal years 2023 to 2026 · $132,781 awarded in 2026
  Same name and institution; not confirmed by an ID
• Project 2 - Targeted Therapies for T-ALL.
  P50CA171963 · NCI · WASHINGTON UNIVERSITY · fiscal years 2013 to 2022 · $329,044 awarded in 2022
  Grant number is on one of their registry trials
• Targeting Leukemia Stromal Interactions in AML
  K23CA140707 · NCI · WASHINGTON UNIVERSITY · fiscal years 2009 to 2013 · $158,853 awarded in 2013
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Alliance for Clinical Trials in Oncology Member Site Core
  U10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026
  Named on NCT03701308, NCT01253070
• Cancer and Leukemia Group B
  U10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013
  Named on NCT01253070